La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Minerva Surgical Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Minerva Surgical ha un patrimonio netto totale di $20.3M e un debito totale di $39.5M, che porta il suo rapporto debito/patrimonio netto a 195.2%. Le sue attività totali e le sue passività totali sono rispettivamente $72.8M e $52.5M.

Informazioni chiave

195.2%

Rapporto debito/patrimonio netto

US$39.53m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$11.13m
Patrimonio netto	US$20.26m
Totale passività	US$52.53m
Totale attività	US$72.79m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Aug 11

Minerva downgraded at JPMorgan citing lowered guidance

Aug 10

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 10

Minerva Surgical - Uterine Play For Sale

Nov 02

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $40.0M ) di UTRS superano le sue passività a breve termine ( $21.3M ).

Passività a lungo termine: Le attività a breve termine di UTRS ( $40.0M ) superano le sue passività a lungo termine ( $31.3M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 140.3% ) di UTRS è considerato alto.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di UTRS si sia ridotto negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: Dati insufficienti per determinare se UTRS ha una pista di cassa sufficiente in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Dati insufficienti per determinare se UTRS ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

Minerva Surgical Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Minerva Surgical Files Form 15

Minerva Surgical, Inc. Announces Voluntary SEC Deregistration and Nasdaq Delisting

Minerva Surgical Receives Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

Minerva Surgical Receives Notification Regarding Minimum Bid Price from the Listing Qualifications Department of the Nasdaq

Recent updates

Minerva Surgical Files Form 15

Minerva Surgical, Inc.(OTCPK:UTRS) dropped from NASDAQ Composite Index

Minerva Surgical, Inc. Announces Voluntary SEC Deregistration and Nasdaq Delisting

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Minerva Surgical, Inc. Announces the Resignation of Jill D. Anderson from the Board of Directors

Minerva Surgical, Inc. announced that it expects to receive $20 million in funding from Accelmed Partners

Consensus EPS estimates upgraded to US$0.22 loss

Minerva Surgical, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Minerva Surgical, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Minerva Surgical, Inc. Announces Resignation of Ross A. Jaffe from the Board and from the Compensation Committee of the Board

Minerva Surgical Provides Revenue Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings released: US$1.18 loss per share (vs US$3.06 loss in FY 2021)

Minerva Surgical, Inc. announced that it has received $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

High number of new directors

Minerva Surgical, Inc. Announces Resignation of David M. Renzi from Board of Directors and as Chairman of its Nominating and Corporate Governance Committee

Minerva Surgical Receives Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

Minerva Surgical, Inc. Announces Management Changes

Minerva Surgical, Inc. announced that it expects to receive $30 million in funding from Accelmed Partners, New Enterprise Associates, Inc.

Consensus forecasts updated

Minerva Surgical, Inc. Provides Revenue Guidance for 2022

Third quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$5.00

Minerva Surgical Receives Notification Regarding Minimum Bid Price from the Listing Qualifications Department of the Nasdaq

Minerva Surgical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 44% Undervaluation?

Minerva downgraded at JPMorgan citing lowered guidance

Minerva Surgical, Inc. Revises Revenue Guidance for the Year 2022

Minerva Surgical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Minerva Surgical, Inc. Appoints Derrick Sung as Director

Minerva Surgical, Inc.(NasdaqGM:UTRS) dropped from Russell Microcap Value Index

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Earnings Guidance for 2022

Minerva Surgical, Inc., Annual General Meeting, Jun 09, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2022

Minerva Surgical, Inc. (NASDAQ:UTRS) Just Reported Earnings, And Analysts Cut Their Target Price

Full year 2021 earnings: EPS exceeds analyst expectations

Minerva Surgical, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Minerva Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

President recently bought US$123k worth of stock

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Minerva Surgical, Inc. Provides Revenue Guidance for the Full Year 2021

Minerva Surgical - Uterine Play For Sale

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane